Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Ankylosing Spondylitis: How Have Biological Therapies Affected the Market?

Published by: Decision Resources

Published: Mar. 23, 2009 - 35 Pages


Table of Contents



Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Disease Overview

Disease Defi nition, Pathophysiology, and Etiology

Symptoms and Peripheral Involvement

Diagnosis and Disease Progression

Current Treatment

Nonsteroidal Anti-Infl ammatory Drugs

Conventional Disease-Modifying Antirheumatic Drugs

TNF-Alpha Inhibitors

Corticosteroids

Bisphosphonates

Epidemiology

Overview

Methods

Emerging Therapies for Ankylosing Spondylitis

Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe’s Golimumab

Pozen/AstraZeneca’s PN-200/PN-400

Novartis’s AIN-457

Array BioPharma’s ARRY-371797

2007 Market and Outlook

Bibliography—Ankylosing Spondylitis

Tables

1. Criteria Used in Evaluating Ankylosing Spondylitis

2. Nonsteroidal Anti-Infl ammatory Agents Commonly Prescribed for Ankylosing Spondylitis

3. Tumor Necrosis Factor-Alpha Inhibitors Approved for the Treatment of Ankylosing Spondylitis

4. Agents in Development for the Treatment of Ankylosing Spondylitis

5. Sales of Drugs to Treat Ankylosing Spondylitis in the United States and Europe, 2007

Figures

1. Rheumatologist-Estimated Percentage of Ankylosing Spondylitis Patients with Specifi c Ankylosing Spondylitis Symptoms

2. Survey question: Please indicate your fi rst-, second-, and third-line therapy choice for the treatment of ankylosing spondylitis

3. Survey question: What percentage of your ankylosing spondylitis patients require new or additional therapies within these time frames?

4. Surveyed Rheumatologist Opinion on Why Tumor Necrosis Factor-Alpha Inhibitors Are Not Prescribed as a First-line Therapy for Ankylosing Spondylitis

5. Prevalent Cases of Ankylosing Spondylitis

6. Survey question: Would you switch your ankylosing spondylitis patients currently taking other tumor necrosis factor-alpha inhibitors to golimumab once the agentis available?

7. Survey question: Will you prescribe Pozen’s PN-200/PN-400 to your ankylosing spondylitis patients?

8. Survey question: What agents do you think are most likely to be replaced by Pozen’s PN-200/PN-400?

9. Survey question: Will you prescribe Novartis’s AIN-457 to your ankylosing spondylitis patients?

Abstract

Introduction

The availability of TNF-á inhibitors fueled a tremendous year-on-year increase in the ankylosing spondylitis (AS) market from 2006 to 2007, and we expect signifi cant growth to continue over the next ten years. Although these agents may establish themselves as the gold-standard treatment for AS, emerging agents can still capitalize on the need for lower-priced, convenient, and effi cacious agents. Thus, the AS market continues to represent an opportunity for companies.

Get the Answers You Need to Shape Your Strategy
  • AS is a chronic, debilitating disease that signifi cantly affects patients’ quality of life. How many
    • people in the United States and Europe have AS? How will this population grow over the next ten years? What are the issues surrounding the diagnosis of AS?
  • Diagnosis of AS is often delayed for years after the onset of symptoms. What are the symptoms of AS? How is the disease diagnosed? What are the risk factors for the disease?
  • The availability of TNF-á inhibitors has changed the approach to AS treatment. What are rheumatologists’ preferred treatments for AS? How robust is the pipeline of developmental AS agents? How will these agents fi t into the treatment algorithm for AS?
  • The AS market has experienced strong growth over the past few years. What was the size of the 2007 AS market? What drugs are the market leaders? Will emerging agents be able to establish themselves in the AS market?
Scope
  • Primary research: survey of U.S. rheumatologists.
  • Overview of AS: etiology, symptoms, and diagnosis.
  • Current treatments: nonsteroidal anti-infl ammatory agents, disease-modifying antirheumatic drugs, TNF-á inhibitors, corticosteroids, and bisphosphonates.
  • Epidemiology: prevalent cases of AS in the United States, France, Germany, Italy, Spain, and the United Kingdom.
  • Emerging agents: Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe’s golimumab; Pozen/AstraZeneca’s PN-400; Novartis’s AIN-457; Array BioPharma’s ARRY-371797.
  • Market overview: 2007 AS market; outlook for current and emerging agents.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009